conclus
daili
intak
mg
bno
day
effect
treatment
acut
viral
rhinosinus
object
pool
efficaci
data
two
similar
random
placebocontrol
clinic
trial
analyz
safeti
evalu
basi
individu
trial
method
efficaci
analysi
base
patient
treatment
perform
oral
either
mg
bno
n
placebo
n
day
trial
patient
underw
five
visit
investig
site
symptom
evalu
accord
epo
guidelin
ultrasonographi
use
confirm
diagnosi
onset
treatment
remiss
symptom
last
visit
efficaci
evalu
investig
mean
major
symptom
score
mss
end
treatment
visit
day
patient
report
symptom
social
emot
consequ
rhinosinus
use
qualiti
life
questionnair
gav
result
mss
improv
treatment
period
mean
score
point
bno
placebo
differ
treatment
group
end
therapi
score
point
p
patientassess
qualiti
life
p
statist
signific
favor
bno
openaccess
articl
distribut
term
ccbyncnd
licens
permit
user
download
share
articl
noncommerci
purpos
long
articl
reproduc
whole
without
chang
provid
origin
sourc
credit
recent
year
concept
rhinosinus
introduc
elucid
inflamm
occur
simultan
nose
paranas
sinus
rhinosinus
usual
involv
one
sever
paranas
sinus
might
confirm
ultrasonographi
opacif
xray
investig
accord
european
posit
paper
rhinosinus
nasal
polyp
epo
acut
rhinosinus
ar
definedbesid
inflamm
nose
paranas
sinusesbi
two
follow
characterist
symptom
nasal
congest
secret
combin
facial
pain
pressur
lossreduct
smell
addit
symptom
fever
fatigu
headach
may
occur
acut
rhiniti
first
step
develop
rhinosinus
demarc
acut
chronic
rhinosinus
mainli
defin
length
diseas
specif
symptom
accord
definit
epo
ar
complet
heal
without
remain
symptom
week
chronic
rhinosinus
one
sever
symptom
still
remain
period
acut
viral
rhinosinus
last
less
day
acut
postvir
rhinosinus
persist
day
latter
case
often
biphas
symptom
pattern
persist
impair
symptom
end
period
ar
predominantli
caus
number
virus
rhinoviru
coronaviru
influenza
virus
induc
increas
proinflammatori
cytokin
neutrophil
similar
type
reaction
occur
also
bacteri
infect
thu
ar
easili
misdiagnos
bacteri
infect
therefor
treat
antibiot
stage
diseas
improv
heal
ar
common
infecti
diseas
enorm
socioeconom
impact
societi
besid
individu
discomfort
reduc
qualiti
life
treatment
strategi
reduc
sever
symptom
minim
durat
diseas
prevent
complic
well
develop
chronic
diseas
recent
year
new
treatment
modal
ar
introducedphytotherapeut
agent
bno
bionorica
se
neumarkt
germani
novel
drug
base
dri
extract
fix
combin
five
herbal
drug
compris
gentian
root
gentiana
radix
primula
flower
primula
flo
sorrel
herb
rumici
herba
elder
flower
sambuci
flo
verbena
herb
verbena
herba
ratio
drug
standard
highdosag
product
treatment
ar
pharmacodynam
studi
demonstr
vitro
anim
model
bno
antimicrobi
antivir
effect
includ
secretolyt
antiinflammatori
activ
previou
phase
studi
document
posit
efficaci
safeti
bno
daili
dose
mg
id
day
confirm
subsequ
confirmatori
phase
trial
present
evalu
data
phase
phase
trial
pool
confirm
observ
treatment
effect
bigger
patient
popul
analysi
base
patient
compar
efficaci
mg
bno
daili
mg
placebo
treatment
ar
analysi
pool
data
inclus
criteria
trial
appli
adult
outpati
sex
age
year
clinic
diagnosi
ar
confirm
ultrasonographi
maxillari
sinus
patient
consid
analysi
ar
defin
sudden
onset
least
three
main
symptom
rhinorrheaanterior
discharg
postnas
drip
nasal
congest
headach
facial
painpressur
enrol
symptom
must
last
day
less
includ
patient
must
present
investigatorevalu
major
symptom
score
mss
maxim
score
point
addit
nasal
congest
must
present
mild
moder
facial
painpressur
score
facial
pain
limit
moder
intens
confin
enrol
patient
noncompl
ar
patient
treat
corticosteroid
antibiot
local
system
within
week
first
visit
investig
inclus
visit
exclud
also
compris
subject
use
medic
common
coldlik
symptom
immunomodul
drug
within
day
inclus
pregnant
lactat
women
subject
sever
diseas
kidney
liver
sever
somatopath
neurolog
andor
psychiatr
diseas
analysi
base
two
similar
prospect
random
doubleblind
placebocontrol
parallelgroup
multicent
studi
perform
center
specialist
otorhinolaryngolog
specialist
intern
medicin
gener
practition
across
germani
visit
outpati
suffer
ar
includ
random
provid
written
consent
treatment
perform
oral
either
mg
bno
placebo
day
treatment
alloc
studi
accord
ratio
neither
subject
investig
knew
ident
medic
allow
treatment
doubleblind
manner
patient
document
symptom
daili
treatment
phase
everyvisit
toth
studi
center
day
visit
respect
investig
evalu
five
symptom
mss
respons
treatment
addit
visit
patient
complet
healthrel
qualiti
life
questionnair
sinonas
outcom
german
adapt
version
gav
ultrasonographi
paranas
sinus
perform
studi
first
visit
confirm
diagnosi
ultrasonographi
end
treatment
visit
perform
second
studi
studi
approv
german
author
receiv
favor
opinion
ethic
committe
accord
declar
helsinki
ich
harmonis
tripartit
guidelin
good
clinic
practic
cpmpich
efficaci
end
point
efficaci
analys
base
pool
data
trial
see
section
statist
analysi
primari
end
point
pool
analysi
set
mean
mss
visit
day
full
analysi
set
fa
perprotocol
popul
pp
addit
singl
symptom
mss
visit
day
analyz
fa
pp
furthermor
symptom
score
total
sum
visit
day
visit
day
analyz
fa
pp
addit
respond
classifi
investig
rate
scale
visit
day
visit
day
visit
day
visit
day
analyz
fa
pp
assess
symptom
sever
investig
rate
sever
five
symptom
mss
visit
use
fourpoint
rate
scale
increas
sever
nonenot
present
mild
moder
sever
pain
paramet
postnas
drip
rate
accord
patient
descript
major
symptom
score
mss
mss
combin
five
relev
symptom
rhinosinus
base
expert
clinician
recommend
rhinorrhea
anterior
discharg
postnas
drip
nasal
congest
headach
facial
painpressur
employ
primari
efficaci
criterion
sever
clinic
trial
mss
calcul
sum
five
singl
symptom
assess
overal
respons
treatment
assess
investig
visit
use
fourpoint
rate
scale
symptom
healedcur
symptom
improv
compar
visit
symptom
unchang
compar
visit
symptom
deterior
compar
visit
patient
cure
report
improv
symptom
rate
score
classifi
respond
wherea
patient
unchang
deterior
symptom
rate
score
classifi
nonrespond
gener
definit
popul
treatment
arm
placebo
bno
mg
trial
includ
combin
analysi
inclus
exclus
criteria
appli
combin
analysi
patient
studi
facial
painpressur
mss
mss
inclus
exclud
analysi
set
violat
inclus
criterion
alloc
patient
differ
analysi
set
done
accord
blind
review
meet
respect
trial
analysi
set
handl
miss
data
efficaci
analys
perform
primarili
fa
compris
data
random
patient
acut
rhinosinus
receiv
least
one
dose
studi
medic
least
one
evalu
efficaci
pp
compris
random
patient
fa
exclud
major
protocol
violat
evalu
safeti
pool
data
perform
instead
safeti
evalu
popul
sep
trial
use
describ
safeti
result
baselin
data
use
imput
miss
valu
case
earli
dropout
patient
due
insuffici
efficaci
fa
popul
gener
case
miss
valu
result
situat
patient
recov
diseas
discontinu
studi
last
document
valu
efficaci
end
point
use
imput
respect
miss
valu
concern
follow
visit
perform
last
observ
carri
forward
locf
case
patient
withdrew
studi
reason
associ
studi
medic
unexpect
worsen
diseasecondit
studi
lack
efficaci
worst
categori
use
global
assess
efficaci
investig
case
miss
item
valu
calcul
symptom
score
worst
item
categori
use
two
item
valu
miss
otherwis
regard
miss
data
analyz
use
sa
version
statist
softwar
statist
test
perform
onesid
p
valu
indic
statist
signific
indic
otherwis
deviat
indic
standard
error
mean
sem
efficaci
analys
perform
pool
data
set
see
statist
analys
analysi
pool
data
primari
end
point
evalu
use
analysi
covari
ancova
differ
one
score
point
mss
treatment
group
prospect
analog
judg
clinic
relev
secondari
end
point
analyz
explor
categor
variabl
test
chisquar
test
continu
data
analyz
ancova
similarli
primari
end
point
cochranmantelhaenszel
test
baselin
valu
compar
treatment
group
test
mannwhitneywilcoxon
test
continu
variabl
chisquar
test
categor
test
patient
alloc
shown
figur
total
patient
alloc
bno
treatment
group
wherea
alloc
placebo
group
pool
data
set
also
random
patient
consid
fa
bno
group
placebo
group
criteria
pp
fulfil
patient
bno
group
patient
placebo
group
studi
durat
treatment
complianc
median
particip
studi
day
group
rang
day
bno
day
placebo
complianc
treatment
accord
tablet
count
bno
group
placebo
group
major
symptom
score
mss
baselin
mean
mss
enrol
without
statist
differ
two
treatment
group
tabl
mss
improv
gradual
group
treatment
period
mean
bno
placebo
tabl
figur
differ
treatment
group
visit
statist
signific
favor
bno
product
fa
p
obviou
differ
mss
two
group
alreadi
evid
visit
day
indic
faster
recoveri
bno
group
show
differ
score
point
mean
score
valu
figur
show
combin
analysi
respons
heal
improv
treatment
visit
day
visit
day
qualiti
life
measur
total
score
result
shown
tabl
iv
highli
signific
differ
favor
bno
evid
end
treatment
p
safeti
result
seriou
advers
event
sae
report
either
trial
total
advers
event
ae
occur
patient
sep
safeti
evalu
popul
n
ae
patient
analysi
show
oral
administr
mg
mg
herbal
drug
bno
effect
tabl
ii
demonstr
antivir
activ
stimul
beat
frequenc
human
respiratori
epithelia
vitro
activ
forskolinstimul
chlorid
secret
bno
dri
extract
without
excipi
wherea
bno
excipi
ad
technic
reason
exampl
enabl
extract
press
tablet
clinic
evid
bno
sinupret
constitu
bno
lower
dose
treatment
sinus
recent
review
show
favor
effect
herbal
medicin
product
exert
signific
oral
antiinflammatori
effect
reduct
cyclooxygenas
cox
express
prostaglandin
pg
e
format
thu
mode
action
ration
therapeut
use
treatment
sinus
viralmicrobi
nasal
infect
associ
inflamm
experiment
studi
sinupret
show
reduct
bacteri
growth
day
herbalsalthough
chemic
less
defin
sinupretseem
similarli
antiinflammatori
effect
exampl
chronic
sinus
although
intranas
corticosteroid
alon
combin
antibiot
gener
recommend
ar
seem
need
document
clinic
use
recent
metaanalysi
efficaci
intranas
corticosteroid
mometason
treatment
ar
show
number
need
treat
improv
resolv
symptom
bno
number
need
treat
calcul
pool
data
set
thu
herbal
drug
bno
seem
least
equal
beneficialor
even
beneficialthan
local
appli
corticosteroid
treatment
ar
use
mss
analysi
accord
epo
recommend
combin
five
relev
symptom
ar
often
use
standard
primari
efficaci
criteria
clinic
studi
furthermor
ultrasonographi
confirm
treatment
effect
analysi
togeth
studi
clinic
efficaci
bno
first
wellcontrol
investig
assess
effect
fix
dose
combin
herb
fulfil
current
qualiti
standard
prospect
doubl
blind
random
placebocontrol
gold
standard
treatment
ar
antibiot
indic
treatment
uncompl
ar
great
number
differ
virus
caus
ar
made
difficult
manufactur
effect
vaccin
socioeconom
cost
diseas
tremend
high
requir
healthcar
resourc
lead
loss
product
averag
everi
adult
becom
affect
upper
respiratori
diseas
two
five
time
per
year
perspect
everi
treatment
modal
shorten
length
diseas
improv
qualiti
life
individu
patient
benefici
societi
individu
sae
occur
bno
frequenc
intens
ae
similar
bno
placebo
conclud
bno
similar
safeti
profil
placebo
accordingli
bno
favor
benefitrisk
ratio
conclus
analysi
confirm
result
confirmatori
phase
trial
bno
analysi
demonstr
daili
intak
mg
bno
week
safe
effect
treatment
option
uncompl
ar
drug
provid
faster
clinic
relev
remiss
symptom
improv
qualiti
life
compar
placebo
